Welcome to our dedicated page for NYXOAH S A SEC filings (Ticker: NYXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nyxoah SA filings document the company's foreign-private-issuer reporting for its medical-technology business and the Genio system for obstructive sleep apnea. Form 6-K reports furnish quarterly and annual operating results, press releases, manufacturing-capacity updates, clinical and regulatory disclosures, and information incorporated by reference into registration statements on Form S-8 and Form F-3.
The filing record also covers capital-structure and governance matters, including ordinary-share offerings, underwriting agreements, shareholder voting matters, transparency-related ownership information, material-event reports, and exhibits that describe financing terms and public-company obligations.
Nyxoah furnished a Form 6-K stating that on November 13, 2025 it announced its unaudited third quarter 2025 results. Those results are contained in a Third Quarter 2025 report attached as Exhibit 99.1. The company also states that the information in Exhibit 99.1 is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, so that these offerings will automatically reflect the latest disclosed information.
Nyxoah furnished a Form 6-K stating that on November 13, 2025 it announced its unaudited third quarter 2025 results. Those results are contained in a Third Quarter 2025 report attached as Exhibit 99.1. The company also states that the information in Exhibit 99.1 is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, so that these offerings will automatically reflect the latest disclosed information.
Nyxoah SA submitted a Form 6-K as a foreign private issuer to furnish a company press release. The filing states that on September 23, 2025, Nyxoah issued a press release, which is attached as Exhibit 99.1. The exhibit is being furnished rather than filed, meaning it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Nyxoah SA submitted a Form 6-K as a foreign private issuer to furnish a company press release. The filing states that on September 23, 2025, Nyxoah issued a press release, which is attached as Exhibit 99.1. The exhibit is being furnished rather than filed, meaning it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Nyxoah SA has entered into an underwriting agreement with Morgan Stanley, Stifel and Cantor Fitzgerald to conduct an underwritten public offering of ordinary shares under its existing shelf registration on Form F-3. The company has granted the underwriters a 30-day option to buy additional shares and expects the offering to close around September 23, 2025, subject to customary conditions.
Nyxoah anticipates receiving net proceeds from this equity raise, after underwriting fees and expenses, and states that, based on current plans, the cash from this offering together with existing cash, cash equivalents and financial assets should be sufficient to fund operating expenses and capital expenditures for an extended period, as outlined in the cash runway discussion. The filing also notes standard indemnification provisions and includes the underwriting agreement, legal opinion and related press releases as exhibits.
Nyxoah SA has entered into an underwriting agreement with Morgan Stanley, Stifel and Cantor Fitzgerald to conduct an underwritten public offering of ordinary shares under its existing shelf registration on Form F-3. The company has granted the underwriters a 30-day option to buy additional shares and expects the offering to close around September 23, 2025, subject to customary conditions.
Nyxoah anticipates receiving net proceeds from this equity raise, after underwriting fees and expenses, and states that, based on current plans, the cash from this offering together with existing cash, cash equivalents and financial assets should be sufficient to fund operating expenses and capital expenditures for an extended period, as outlined in the cash runway discussion. The filing also notes standard indemnification provisions and includes the underwriting agreement, legal opinion and related press releases as exhibits.
Nyxoah SA reported that it has filed a patent infringement lawsuit in the United States against Inspire Medical Systems, Inc.. The suit, filed in the District of Delaware, alleges that Inspire’s Inspire IV and Inspire V devices infringe three Nyxoah U.S. patents and seeks injunctive relief and damages. Information about the lawsuit is furnished via a press release attached as Exhibit 99.1 and the lawsuit description is incorporated by reference into Nyxoah’s existing Form S-8 and Form F-3 registration statements.
Nyxoah announced U.S. FDA approval of its Genio system for a specific group of adult OSA patients with an Apnea-Hypopnea Index between 15 and 65. The Genio system remains the company’s only commercial product and its future performance depends on physician, payer and patient adoption in target markets.
The company provided preliminary, unaudited Q2 2025 results showing revenue of ~€1.3 million (a 73% increase versus Q2 2024), operating expenses of ~€20.7 million (a 50% increase) and cash, cash equivalents and financial assets of ~€43.0 million as of June 30, 2025. Management expects the ACCCESS clinical study to close enrollment before reaching all 106 potential patients; enrolled patients will be assessed at 12 months post-implant for co-primary endpoints (AHI and ODI) and followed for five years. The company also announced a reorganization to transition ongoing R&D activities to the United States and Belgium. The financial figures are preliminary and unaudited and may change after review.
Nyxoah SA (NASDAQ: NYXH) has submitted a Form 6-K to the U.S. Securities and Exchange Commission for the month of June 2025.
The filing’s sole purpose is to furnish – not file – a press release dated 27 June 2025, which is attached as Exhibit 99.1. No financial statements, earnings data, or transactional details are included in the body of the report. Consistent with Exchange Act rules, the furnished information is explicitly excluded from Section 18 liability and will not be incorporated by reference into other SEC filings unless specifically stated.
The document is signed by Chief Financial Officer John Landry on behalf of the company. Apart from procedural disclosures (paper-filing check boxes, form type election, and signature block), the 6-K contains no additional operational, strategic, or financial commentary. Investors must review Exhibit 99.1 directly to understand the substance of the press release.